Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP)
نویسندگان
چکیده
منابع مشابه
Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
PURPOSE On November 20, 2008, eltrombopag (Promacta) received approval from the US Food and Drug Administration (FDA) for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. This report summarizes the FDA analyses of the clinical data supporting this approval. ...
متن کاملEltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP).
This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of eltrombopag for the treatment of adults with chronic idiopathic (immune) thrombocytopenic purpura (ITP), based on a review of the manufacturer's submission (MS) to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appra...
متن کاملAbout treatment of idiopathic thrombocytopenic purpura (ITP).
Their treatment results with megadose methylprednisolone (MDMP) support fairly closely our complete remission results, though theirs was a retrospective evaluation. In our prospective, comparative study, antiplatelet antibodies were also determined3. Their 80% complete remission rate (mistakenly written as 66% in the text) with MDMP administration was much better than other therapeutic approach...
متن کاملUpdate on chronic immune thrombocytopenic purpura (ITP)
Platelet production and circulation Thrombopoietin (TPO), the major cytokine affecting all phases of platelet production, is produced primarily by the liver and binds to the c-Mpl receptor located on platelets, stem cells and megakaryocytes. Upon stimulation, pluripotential stem cells produce cells committed to megakaryocyte differentiation. These cells initially undergo mitosis followed eventu...
متن کاملRomiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
PURPOSE On August 22, 2008, Romiplostim (Nplate for Injection) received approval from the US Food and Drug Administration (FDA) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. This report summarizes the FDA analyses of the clinical data sup...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Health Technology Assessment
سال: 2011
ISSN: 1366-5278,2046-4924
DOI: 10.3310/hta15suppl1/03